Black Diamond Therapeutics, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BDTX research report →
Range $8 – $20
Price Chart
About the company
Black Diamond Therapeutics, Inc. is a biotechnology enterprise dedicated to discovering, advancing, and bringing to market therapeutic agents specifically designed for patients with genetically characterized tumors. A core part of its pipeline is BDTX-189, an irreversible small molecule inhibitor.
- CEO
- Mark A. Velleca
- IPO
- 2020
- Employees
- 21
- HQ
- Cambridge, MA, US
Get TickerSpark's AI analysis on BDTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $123.34M
- P/E
- -2.91
- PEG
- 0.01
- P/S
- 0.00
- P/B
- 1.29
- EV/EBITDA
- -2.96
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -38.80%
- ROIC
- -45.91%
Latest fiscal year · YoY change
- Revenue
- $70.00M+0.0%
- Gross Profit
- $69.67M+0.0%
- Op Income
- $19.87M
- Net Income
- $22.37M+132.1%
- EPS
- $0.39+130.7%
- OCF Growth
- +147.5%
- FCF Growth
- +147.5%
- 52W High
- $4.94
- 52W Low
- $1.60
- 50D MA
- $1.86
- 200D MA
- $2.50
- Beta
- 3.29
- RSI (14)
- 62
- Avg Volume
- 1.33M
No earnings-call transcripts are available for BDTX yet.
- Free Float
- 80.3%
- Shares Outstanding
- 57.30M
- Float Shares
- 46.02M
of shares held by institutions
110 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 2.19M | 0 |
| Two Sigma Advisers, LP | 28.60K | ▲ 14.60K |
| Point72 Asia (Singapore) Pte. Ltd. | 20.61K | ▲ 2.77K |
| Sherbrooke Park Advisers LLC | 12.05K | ▲ 12.05K |
| Point72 (Difc) Ltd | 143 | ▼ 7.08K |
| Cwm, LLC | 74 | ▼ 291 |
Held by 90 ETFs
Biggest fund positions in BDTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 26, 26 | Behbahani Ali | other | 40,000 |
| Jun 26, 26 | Kulkarni Samarth | other | 40,000 |
| Jun 26, 26 | Menzel Garry E | other | 40,000 |
| Jun 26, 26 | Raman Prakash | other | 40,000 |
| Jun 26, 26 | Dhingra Kapil | other | 40,000 |
| Jun 26, 26 | Campbell Shannon | other | 40,000 |
| Jun 19, 26 | Behbahani Ali | other | 8,961 |
| Jun 19, 26 | Raman Prakash | other | 7,907 |
| Mar 20, 26 | Behbahani Ali | other | 6,919 |
| Mar 20, 26 | Raman Prakash | other | 6,105 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our BDTX coverage
Recent articles, reports, and earnings notes.
Want a deeper read on BDTX?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Black Diamond Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
globenewswire.com · Aug 5
Black Diamond Therapeutics: Positive Phase 2 Results Offer An Upside
seekingalpha.com · Jul 6
BDTX Broadens EGFR Reach into Glioblastoma, Adding a Fresh Catalyst
zacks.com · May 27
Black Diamond Stock Outlook After Q1 Beat and Cash Runway
zacks.com · May 27
BDTX Silevertinib Data in EGFR NSCLC: What Investors Need to Know
zacks.com · May 27
What's Going On With Black Diamond Therapeutics Stock Tuesday?
feeds.benzinga.com · May 26
BDTX Stock Slumps on Mixed Phase II Frontline NSCLC Study Data
zacks.com · May 25
Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
globenewswire.com · May 22
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.